Rare GABRA3 variants are associated with epileptic seizures, encephalopathy and dysmorphic features

Cristina Elena Niturad,1,* Dorit Lev,2,3,4,* Vera M. Kalscheuer,5,6,* Agnieszka Charzewśka,7
Julian Schubert,1,8 Tally Lerman-Sagie,3,4,9 Hester Y. Kroes,10 Renske Oegema,10
Monica Traverso,11 Nicola Specchio,12 Maria Lassota,13 Jamel Chelly,14
Odeya Bennett-Back,15 Nirit Carmi,3,4,10 Tal Koffler-Brill,16 Michele Iacomin⁄,11
Marina Trivisano,12 Giuseppe Capovilla,17 Pasquale Striano,18 Magdalena Nawara,7
Sylvia Rzońca,7 Ute Fischer,5,6 Melanie Bienek,5 Corinna Jensen,5,‡ Hao Hu,5,§
Holger Thiele,19 Janine Altmüller,19,20 Roland Krause,8 Patrick May,8 Felicitas Becker,1
EuroEPINOMICS Consortium, Rudi Balling,8 Saskia Biskup,21 Stefan A. Haas,22
Peter Nürnberg,19 Koen L. I. van Gassen,10 Holger Lerche,1 Federico Zara,11,*
Snezana Maljevic1,*§ and Esther Leshinsky-Silver2,3,16,*†

*These authors contributed equally to this work.
†Deceased.

Genetic epilepsies are caused by mutations in a range of different genes, many of them encoding ion channels, receptors or transporters. While the number of detected variants and genes increased dramatically in the recent years, pleiotropic effects have also been recognized, revealing that clinical syndromes with various degrees of severity arise from a single gene, a single mutation, or from different mutations showing similar functional defects. Accordingly, several genes coding for GABAA receptor subunits have been linked to a spectrum of benign to severe epileptic disorders and it was shown that a loss of function presents the major correlated pathomechanism. Here, we identified six variants in GABRA3 encoding the α3-subunit of the GABAA receptor. This gene is located on chromosome Xq28 and has not been previously associated with human disease. Five missense variants and one microduplication were detected in four families and two sporadic cases presenting with a range of epileptic seizure types, a varying degree of intellectual disability and developmental delay, sometimes with dysmorphic features or nystagmus. The variants co-segregated mostly but not completely with the phenotype in the families, indicating in some cases incomplete penetrance, involvement of other genes, or presence of phenocopies. Overall, males were more severely affected and there were three asymptomatic female mutation carriers compared to only one male without a clinical phenotype. X-chromosome inactivation studies could not explain the phenotypic variability in females. Three detected missense variants are localized in the extracellular GABA-binding NH2-terminus, one in the M2-M3 linker and one in the M4 transmembrane segment of the α3-subunit. Functional studies in Xenopus laevis oocytes revealed a variable but significant reduction of GABA-evoked anion currents for all mutants compared to wild-type receptors. The degree of current reduction correlated partially with the phenotype. The microduplication disrupted GABRA3 expression in fibroblasts of the affected patient. In summary, our results reveal that rare loss-of-function variants in GABRA3 increase the risk for a varying combination of epilepsy, intellectual disability/developmental delay and dysmorphic features, presenting in some pedigrees with an X-linked inheritance pattern.
Introduction

Genetic epilepsy has been commonly associated with alterations in genes coding for ion channels and receptors (Lerche et al., 2013). Recent employment of next generation sequencing techniques, including exome sequencing and whole genome copy number variant analysis, corroborate such observations by identifying a number of novel ion channel and receptor gene variants in epilepsy patients (Veeramah et al., 2012; Weckhuysen et al., 2012; Epi4K Consortium et al., 2013; Carvill et al., 2014; Lemke et al., 2014; Nava et al., 2014; Schubert et al., 2014; Weckhuysen and Korff, 2014; Larsen et al., 2015; Syrbe et al., 2015; Leu et al., 2016; Papandreou et al., 2016; Möller et al., 2017). Apart from identifying novel disease genes, these findings reveal several additional developments. First, they expand the range of syndromes associated with some of the previously identified epilepsy genes. Second, they suggest that severe epileptic encephalopathies, encompassing both refractory seizures and developmental delay often represent sporadic cases, with de novo occurring mutations. Lastly, they point to an increasing number of genes and variants showing a pleiotropic effect, when distinct clinical syndromes with different degrees of severity arise from a single gene, a single variant, or from different variants showing similar functional defects (Claes et al., 2001; Harkin et al., 2007; Veeramah et al., 2012; Weckhuysen et al., 2012; Epi4K Consortium et al., 2013; Suls et al., 2013; Carvill et al., 2014; Nava et al., 2014; Weckhuysen and Korff, 2014; Blanchard et al., 2015; Howell et al., 2015; Syrbe et al., 2015; Epi4K Consortium, 2016; Mørk et al., 2016; Syrbe et al., 2015; Mørk et al., 2016; Shen et al., 2017; Wolff et al., 2017).

GABA is the main inhibitory neurotransmitter in the adult brain. Its action depends on two classes of proteins, ionotropic GABA_A and metabotropic GABA_B receptors, which mediate fast and slow synaptic inhibition, respectively. Furthermore, both receptor types are involved in tonic inhibition. Nineteen different genes from eight different classes encode GABA_A receptor subunits, which combine into heteropentamers to form postsynaptic ligand-gated anion channels. Pentamers usually contain two alpha and two beta subunits, which conjoin with a subunit...
from one of the other classes. Subunit combination determines functional properties of the receptor as well as its spatiotemporal expression pattern (Fritschy and Panzanelli, 2014).

Presuming that neuronal hyperexcitability seen in epilepsy arises from a disturbed balance of inhibitory and excitatory neurotransmission in the brain, it is somewhat surprising that so far only four genes (GABRA1, GABRB3, GABRG2 and GABRD) encoding the α1-, γ2-, β3- and δ-subunits of GABA_A receptors have been directly associated with epilepsy (Macdonald et al., 2012). Initially, the correlated syndromes included childhood absence epilepsy, juvenile myoclonic epilepsy, and febrile seizures with or without epilepsy including generalized/genetic epilepsy with febrile seizures plus (GEFS+) (Baulac et al., 2001; Wallace et al., 2001; Cossette et al., 2002; Harkin et al., 2002; Kananura et al., 2002; Maljevic et al., 2006; Macdonald et al., 2012). Recent studies extended this list to different forms of epileptic encephalopathies, including epilepsy with myoclonic-ataxic seizures and Dravet syndrome (Carvill et al., 2014; Epilepsy Consortium, 2016; Johannesen et al., 2016; Papandreou et al., 2016; Janve et al., 2017; Möller et al., 2017; Shen et al., 2017). The association of a single gene with a spectrum of partially overlapping epileptic phenotypes, from mild to severe ones has been mainly attributed to the brain sodium channel gene SCN1A and to SLC2A1 encoding the GLUT1 transporter (Claes et al., 2001; Harkin et al., 2007; Leen et al., 2010; Lerche et al., 2013; Weckhuysen and Korff, 2014). However, a similar genotype–phenotype correlation pattern has recently also been reported for the GABRA1, GABRB3 and GABRG2 genes encoding γ2-, β3- and γ2- subunits of the GABA_A receptor, respectively (Carvill et al., 2014; Epilepsy Consortium, 2016; Johannesen et al., 2016; Kang and Macdonald, 2016; Möller et al., 2017).

In this study, we identified several variants in the GABRA3 gene, encoding the α3-subunit of GABA_A receptors, in families and sporadic cases affected either by variably severe epilepsy with encephalopathy, or by genetic generalized epilepsy (GGE), presenting a milder form of epilepsy with complex inheritance.

**Materials and methods**

**Patients and cohorts**

Parents or the legal guardian of each patient enrolled in this study signed an informed consent form for participation. The study was approved by the local ethics committees of each participating clinical centre. Genomic DNA of the individuals was extracted from peripheral blood according to standard procedures. The analysed cohorts included: (i) a cohort from the Wolfson Medical Center, Holon, Israel with 15 families with various forms of epilepsy; (ii) a cohort of 480 families with X-linked intellectual disability (XLID) collected by the EURO-MRX consortium and associated groups; (iii) a cohort of 600 cases undergoing diagnostic high-density array-comparative genomic hybridization (CGH) screening; and (iv) a cohort of 238 exome-sequenced cases with GGE collected by the EuroEPINOMICS consortium. Additionally, diagnostic services within the European epilepsy community were also included. Detailed description of the patient cohorts is provided in the Supplementary material.

**Whole exome sequencing**

**Target enrichment**

Whole exome sequencing and target enrichment were performed according to standard procedures at three different centres [Wolfson Medical Center (WMC), Holon, Israel; CegaT GmbH, Tübingen, Germany; Cologne Center for Genomics (CCG), Cologne, Germany]. Samples were enriched with Agilent Sureselect Human All Exon v2 (WMC), or v.5 (CegaT) or v.6 (CCG) kit. Sequencing was carried out on Illumina HiSeq2000 or HiSeq2500 platforms as 100 bp paired-end runs (WMC, CegaT) or 76 bp paired-end runs (CCG).

**Data processing**

Adaptors were removed with Skewer 0.1.1161 (CegaT) or cutadapt (CCG). The data preprocessing and variant calling was performed following the GATK (DePristo et al., 2011) best practice or the Varband pipeline v.2.3 developed by the Cologne Center of Genomics, University Cologne. For alignment of the reads, we used bwa-mem (Li and Durbin, 2009) with default parameters and hg19 as reference. The sam file format was converted to bam files with samtools (Li et al., 2009). The subsequent steps by means of sorting bam files, marking duplicated reads and addition of read groups was performed with default parameters using picard tools (https://github.com/broadinstitute/picard). In order to recalibrate base quality scores and do local realignment, GATK version 3.2 was used. Variant filtering was done using GATK best practice (for SNV: FS > 60.0, QD < 2.0, MQ < 40.0, ReadPosRankSum < −8.0, MQRankSum < −12.5, DP < 10.0, GQ_MEAN < 20.0, VQSLOD < 0, ABHet > 0.75 or < 0.25; For Indel: QD > 2.0, FS > 200, ReadPosRankSum < −20.0, DP < 10.0).

**Variant annotation**

The variants were annotated using ANNOVAR (Wang et al., 2010) (WMC, CegaT, CCG) or additionally by in-house software (CCG). RefSeq, dbNSFP30a (Liu et al., 2011, 2016), cadd20 (Kircher et al., 2014), ClinVar (20150330), HGMD (1000 Genomes Project Consortium et al., 2012), 1000 Genomes, dbSNP (Sherry et al., 2001), ExAC (Lek et al., 2016) (release 0.3) and the EVS (Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (URL: http://evs.gs.washington.edu/EVS/) were used. Non-coding variants and variants with minor allele frequency (MAF) < 0.01 were filtered out. In addition, variants were filtered against in-house database to exclude pipeline-related artefacts (MAF < 0.02). Only variants with a coverage ≥10× were analysed. All genes were filtered for the expression in brain and variants not being located in the repeat regions (Reumers et al., 2011).

Furthermore, we filtered variants to be deleterious when one of the following criteria was fulfilled: the variant had to be (i) predicted by 5 of 11 missense prediction scores (SIFT,
X-chromosome exome sequencing

To identify the disease-causing mutations in families with X-linked intellectual disability we performed X-chromosome exome sequencing using DNA of the index patients and analysed the data, as previously described (Hu et al., 2014, 2016).

Diagnostic panels

After referral for routine diagnostic exome sequencing, exomes of the parents (Families 4 and 5) were enriched using the Agilent SureSelect XT Human All Exon kit V5 (Family 5) and V6 (Family 4) and sequenced in rapid 2 × 100 bp run mode on the HiSeq2500 sequencing system (Illumina) at a mean target depth of 100 ×. The target was defined as all coding exons of UCSC and Ensembl ± 20 bp intron flanks. At this depth > 95% of the target is covered at least 15 ×. Reads were aligned to hg19 using BWA (BWA-MEM v0.7.5a) and variants were called using the GATK haplotype caller (v2.7-2 and v3.4.46). Detected variants were annotated, filtered and prioritized using the Bench NGS Lab platform (Agilent-Cartagenia). Analysis was based on a tiered analysis approach. In the first tier known intellectual disability genes were analysed. This first tier did not lead to a result in the detection of the de novo GABA3 variants. The last tier, which filters for recessive variants, did not result in additional candidates.

Microduplication analysis

Array-CGH was performed on 44k slide (Agilent) as previously described (Coppola et al., 2010). Assays showing a DLRS (derivative of log ratio spread) score > 0.3 were excluded. Detection of gains and losses was performed using the ADM-2 algorithm with a moving average of 500 kb and a threshold of 6.0. To further define genomic breakpoints on Patient II-2 of Family 3, a high-density 244K microarray was performed on 44k slide (Agilent) at a mean target depth of 100 ×. Reads were aligned to hg19 using BWA (BWA-MEM v0.7.5a) and variants were called using the GATK haplotype caller (v2.7-2 and v3.4.46). Detected variants were annotated, filtered and prioritized using the Bench NGS Lab platform (Agilent-Cartagenia). Analysis was based on a tiered analysis approach. In the first tier known intellectual disability genes were analysed. This first tier did not lead to a diagnosis. The second tier, which filters for de novo variants, resulted in the detection of the de novo GABA3 variants. The last tier, which filters for recessive variants, did not result in additional candidates.

Validation of GABA3 variants and segregation analysis

For validation of the GABA3 variants identified in this study and for segregation analysis we used gene-specific primers flanking the exons that harbour the mutations and determined genotypes for all available family members by conventional Sanger sequencing of specific PCR products. Primer sequences are available upon request.

X-inactivation test

To assess the inactivation status of chromosome X in heterozygous female carriers of GABA3 variants we used the human androgen receptor (HUMARA) assay as described (Gibson et al., 2005).

Functional investigations

Mutagenesis and RNA preparation

We used the QuikChange® kit (Stratagene) to engineer five missense mutations, p.T166M, p.Q242L, p.T336M, p.Y474C and p.47R in the GABA3 receptor α3 subunit cDNA (NM_000808) cloned in the pcDNA3 (kind gift from Dr Steven Petrou, Melbourne). All mutations were confirmed and additional changes excluded by Sanger sequencing. Primers are available upon request. cRNA was prepared using the T7 RNA polymerase kit from Roche.

Oocyte preparation and injection

The use of animals and all experimental procedures were approved by local authorities (Regierungspräsidium Tübingen, Tübingen, Germany). Oocytes were obtained from the Institute of Physiology I, Tübingen, or purchased from EcoCyte Bioscience. Preparation of oocytes for recordings included treatment with collagenase (1 mg/ml of type CLS II collagenase, Biochom) in OR-2 solution (in mM: 82.5 NaCl, 2.5 KCl, 1 MgCl2 and 5 HEPES, pH 7.6), followed by thorough washing and storing at 16℃ in Barth solution (in mM: 88 NaCl, 2.4 NaHCO3, 1 KCl, 0.41 CaCl2, 0.82 MgSO4 and 5 Tris/HCl, pH 7.4 with NaOH) supplemented with 50 μg/ml gentamicin (Biochom). To compare current amplitudes of wild-type and mutant channels, the same amounts of cRNA were injected on the same day using the same batch of oocytes plated in 96 well-plates and measured in parallel at Days 1–3 after injection. The combination used was z3β2γ5 in a 1:1:2 ratio. All cRNA concentrations were adjusted to 2 μg/μl and 70 nl of the corresponding cRNA was injected using Roboinjector® (Multi Channel Systems).

Automated oocyte two-microelectrode voltage clamp

GABA-evoked currents in oocytes were recorded at room temperature (20–22℃) using Roboocyte2® (Multi Channel Systems). Pre-pulled and prepositioned intracellular glass microelectrodes had a resistance of 0.3–1 MΩ when filled with 1 M KCl/1.5 M KAc. The bath solution was ND96 (in mM: 93.5 NaCl, 2 KCl, 1.8 CaCl2, 2 MgCl2, 5 HEPES, pH 7.5). Currents were sampled at 1 KHz. GABA-evoked currents were used to analyse the activation of the wild-type using automated two-microelectrode voltage clamping. Different GABA concentrations (in μM: 1, 3, 10, 40, 100, 300, 1000) diluted in ND96 solution were applied for 15 s to activate the channels. The holding potential was −70 mV.

Electrophysiological data analysis

The amplitude of the GABA-induced currents was analysed using Roboocyte2+ (Multi Channel Systems), Clampfit (pClamp 8.2, Axon Instruments), Microsoft Excel (Microsoft, Redmond, WA) and Graphpad Prism software (GraphPad Software). Current response for each GABA concentration
was normalized to the maximum response evoked by the highest GABA concentration. The normalized GABA responses of each cell were fitted to the four-parameter logistic equation:

$$Y = \text{min} + \frac{\text{max} - \text{min}}{1 + 10^{(\log EC_{50} - X)/nH}}$$  

(1)

with max and min being the maximum and minimum evoked responses and X the corresponding GABA concentration. The EC$_{50}$ value is the concentration of the agonist at which half of the maximum response is achieved while the nH presents the steepness of the dose response curve. EC$_{50}$ values were determined for each oocyte and the averaged values for wild-type and each mutation are shown as mean ± standard error of the mean (SEM). Current amplitudes recorded in parallel on the same experimental day in response to 1 mM GABA application from oocytes expressing wild-type or mutant channels, were normalized to the mean value of the wild-type response.

**Western blot analysis**

Injected *Xenopus* oocytes expressing either wild-type or mutant $z_3$$\beta_2$$\gamma_2s$ receptors were lysed in a buffer containing 20 mM Tris, 100 mM NaCl, 1 mM EDTA, 0.5% Triton$^\text{TM}$ X-100 and 10% glycerol with cOmplete protease inhibitors (Roche). Water-injected oocytes were used as a control. Protein concentration was measured (DC Protein Assay, Bio-Rad) and 25 µg of protein was separated using SDS-PAGE on 8% polyacrylamide gels. After the transfer onto nitrocellulose membrane (Protran®, Whatman), protein detections were performed using a rabbit polyclonal antibody against the GABA$\alpha_3$ receptor $\alpha_3$-subunit (1:250; HPA000839 Sigma) and against actin (1:1000; Sigma A3853) as a loading control. Quantification of signals was performed using ImageJ software (NIH). Expression levels were normalized to actin and pooled from four different experiments.

**Statistical analysis**

Data were tested for normal distribution using GraphPad Prism 6 (GraphPad Software). Groups were compared using one-way ANOVA with Dunnett’s post hoc test for normally distributed data or one-way ANOVA on ranks with Dunn’s post hoc test for not normally distributed data. All data are presented as mean ± SEM. Statistiscal differences are indicated in the figure legends using the following symbols: *$P$ < 0.05, **$P$ < 0.001, ***$P$ < 0.0001.

**Results**

The study was initiated by recruitment of 15 families with various forms of epilepsy (Supplementary material), including Family 1 of Israeli Jewish origin, in which the disease status of affected individuals was indicative of an X-linked inheritance. Two males in this pedigree (Fig. 1A) were severely affected with pharmacoresistant epileptic encephalopathies with infantile or childhood onset, featuring infantile spasms, tonic and generalized tonic-clonic seizures, moderate-to-severe intellectual disability and developmental delay.

---

**Figure 1** Novel GABRA3 pathogenic variant associated with severe epileptic encephalopathy. (A) Pedigree of Family 1 and cosegregation of the genomic A>T exchange with the disorder. (B) Photographs of Patient III-1 from Family 1, carrying the p.Q242L mutation, at 5 and 16 years of age showing micrognathia, sloping shoulders and short neck. (C) Sanger sequence chromatograms from three individuals of Family 1. (D) p.Q242L amino acid exchange and evolutionary conservation of the mutated amino acid. DF = dysmorphic features; ID = intellectual disability; WES = whole exome sequencing.
with speech problems. In contrast, two affected females had a much milder phenotype, which included well treatable generalized tonic-clonic seizures and mild learning disability. All of them had micrognathia, short stature and further dysmorphic features (Fig. 1B), as well as nystagmus. Additionally, cleft palate was present in all but Patient III-2 (Table 1 and Supplementary material). Whole exome sequencing in Patient III-1 of this family (Fig. 1A) revealed a variant in GABRA3 as the most plausible disease causing change identified on chromosome X (c.725A>T, p.Q242L, Fig. 1C) (Supplementary material). The p.Q242 is a highly conserved amino acid (Fig. 1D). The variant is predicted to be deleterious according to PolyPhen-2, SIFT and MutationTaster, and is found neither in the ExAC (exome aggregation consortium) database nor in gnomAD (genome aggregation database) (Supplementary Table 1). Direct sequencing in the whole family revealed perfect cosegregation showing that all affected individuals (mother, two affected sons, and daughter) carry the same p.Q242L variant, whereas the healthy son, grandmother, maternal aunts and uncle do not carry this variant (Fig. 1A). To exclude further disease-associated variants, we performed exome sequencing of the remaining three affected individuals and the healthy brother. Among the variants shared by the affected, but not the healthy individual, we found no particular changes in genes that had been previously associated with dysmorphic features, intellectual disability or epilepsy (Supplementary Table 2). We thus assume that the p.Q242L variant is pathogenic and mainly responsible for all clinical features observed in this family.

To further assess the role of GABRA3 in epilepsy and intellectual disability, we selected three clinical cohorts according to the main clinical features of Family 1: a cohort of 480 families with X-linked intellectual disability (XLID) collected by the EURO-MRX consortium and associated groups, a cohort of 600 cases undergoing diagnostic high-density array-CGH screening, and an exome-sequenced group of 480 families with X-linked intellectual disability (XLID) (Supplementary Table 3). We further aimed to identify copy number variants involving GABRA3 by analysing a cohort of patients affected by epilepsy and intellectual disability (n = 103), only epilepsy (n = 198) or intellectual disability without epilepsy (n = 299), who underwent diagnostic high-density array-CGH screening. An intragenic microduplication encompassing exons 1–3 of GABRA3 (chrX:152277607-152451201, GRCh38/hg38; arr[hg38]Xq28(152.277.607-152.451.201) x2) was identified in a male affected by pharmacoresistant epilepsy with weekly generalized seizures, generalized spike-and polyspike-wave discharges in EEG, but without any dysmorphic signs or nystagmus (Family 3) (Fig. 3A, C, Table 1 and Supplementary material). The duplication was inherited from a healthy mother. No deletions or duplications affecting GABRA3 were identified in a cohort of 273 in-house controls. In addition, no copy number variants encompassing the coding region of GABRA3 have been reported in the database of genomic variants (DGV database). We demonstrated that the rearrangement disrupts the expression of the gene in cultured fibroblasts from the patient, providing additional evidence for a pathogenic loss-of-function GABRA3 variant (Fig. 3B). Furthermore, whole exome sequencing was performed in this family to exclude any other potentially pathogenic variants, in particular those

mother (Patient II:6) suffered from absences. Their sister (Patient III:12) carries the variant and has learning problems. The two other male mutation carriers in another branch of the family have different phenotypes—one of them has intellectual disability (Patient III:7) and the other is unaffected (Individual III:6). Their mother, who is a mutation carrier, suffered from absence seizures. Another affected male in the family (Patient III:4) also has intellectual disability but was unavailable for molecular testing. Recent clinical re-evaluation of the proband and his brother revealed dysmorphic features similar to those seen in affected individuals of Family 1 (e.g. nystagmus, micrognathia, arched palate) (Table 1 and Supplementary material). However, some of the observed traits are specific for Family 2 (Table 1, Fig. 2B and Supplementary material). Opposite to the short stature and overall present dysmorphic features seen in Family 1, affected Family 2 members present with a tall and thin stature and more pronounced dysmorphism in males. The absence of the cleft palate in Family 2 members is another distinctive feature. The detected GABRA3 variant c.497C>T, p.T166M (Fig. 2C) affects a highly conserved amino acid in the N-terminal sequence of the GABA\(_\text{A}\) receptor \(\gamma_2\)-subunit (Fig. 2D) and is predicted to be deleterious by \textit{in silico} analysis. While it is not present in ExAC, one case has now been reported in gnomAD with a frequency of \(5.61 \times 10^{-6}\) (Supplementary Table 1). To verify that no additional pathogenic autosomal variants were present in this family, whole exome sequencing was performed on Individuals II:1, III:3 III:6, III:7, III:10, III:12, and III:13 with no other genes emerging as directly related to the disease phenotype or explaining the inheritance pattern (Supplementary Table 3).

We further aimed to identify copy number variants involving GABRA3 by analysing a cohort of patients affected by epilepsy and intellectual disability (n = 103), only epilepsy (n = 198) or intellectual disability without epilepsy (n = 299), who underwent diagnostic high-density array-CGH screening. An intragenic microduplication encompassing exons 1–3 of GABRA3 (chrX:152277607-152451201, GRCh38/hg38; arr[hg38]Xq28(152.277.607-152.451.201) x2) was identified in a male affected by pharmacoresistant epilepsy with weekly generalized seizures, generalized spike-and polyspike-wave discharges in EEG, but without any dysmorphic signs or nystagmus (Family 3) (Fig. 3A, C, Table 1 and Supplementary material). The duplication was inherited from a healthy mother. No deletions or duplications affecting GABRA3 were identified in a cohort of 273 in-house controls. In addition, no copy number variants encompassing the coding region of GABRA3 have been reported in the database of genomic variants (DGV database). We demonstrated that the rearrangement disrupts the expression of the gene in cultured fibroblasts from the patient, providing additional evidence for a pathogenic loss-of-function GABRA3 variant (Fig. 3B). Furthermore, whole exome sequencing was performed in this family to exclude any other potentially pathogenic variants, in particular those
Table 1 Clinical characteristics of affected members in families with identified GABRA3 alterations

<table>
<thead>
<tr>
<th>Individual</th>
<th>Sex, age at last follow-up</th>
<th>Seizures (onset/ end in y)</th>
<th>Type of seizures</th>
<th>EEG</th>
<th>Treatment</th>
<th>Additional symptoms (morphological features)</th>
<th>Behavioural symptoms and development</th>
<th>GABRA3 variant</th>
<th>X-chromosome inactivation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Family F1 (Israel)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II-2</td>
<td>F</td>
<td>21</td>
<td>Tonic-clonic</td>
<td>Slowing of background EEG activity</td>
<td>CBZ</td>
<td>Cleft palate, nystagmus, microretrognathia, synophrys</td>
<td>Mild developmental delay, learning disabilities</td>
<td>c.725A&gt;T</td>
<td>0.32 versus 0.68</td>
</tr>
<tr>
<td>III-1</td>
<td>M, 18</td>
<td>3</td>
<td>Infantile spasms, Lennox-Gastaut</td>
<td>Right parietal spikes at the age of 7m</td>
<td>ACTH, VIG, CLZ, LEV, VPA, RIFM, LTG, VPA</td>
<td>Cleft palate, nystagmus, microretrognathia, sloping shoulders, short neck</td>
<td>Severe intellectual disability</td>
<td>c.725A&gt;T</td>
<td>0.38 versus 0.62</td>
</tr>
<tr>
<td>III-2</td>
<td>F, 14</td>
<td>7</td>
<td>Tonic-clonic</td>
<td>Short bursts of spikes and multi spikes. Slowing of background EEG activity</td>
<td>LTG, VPA</td>
<td>Retrognathia, sloping shoulders, fine nystagmus</td>
<td>Mild learning disability</td>
<td>c.725A&gt;T</td>
<td></td>
</tr>
<tr>
<td>III-3</td>
<td>M</td>
<td>3</td>
<td>Epileptiform spasms and tonic seizures</td>
<td>Slowing over the left centroparietal region; beta activity; polymorphic delta waves and spike and wave complexes over the left fronto-central region</td>
<td>LEV, CLB, CBZ, LTG</td>
<td>Cleft palate, micrognathia, short neck, nystagmus, sloping shoulders</td>
<td>Global developmental delay, walking at age 3y, speech starting at age 6y, Moderate intellectual disability</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>III-4</td>
<td>M</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>c.497C&gt;T</td>
<td></td>
</tr>
<tr>
<td><strong>Family F2 (Poland)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II-1</td>
<td>M, -</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>Intellectual disability</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>II-2</td>
<td>F, -</td>
<td>5 / 14</td>
<td>Generalized epilepsy</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>Learning difficulties</td>
<td>Likely, not tested</td>
<td>c.497C&gt;T</td>
</tr>
<tr>
<td>II-4</td>
<td>F, -</td>
<td></td>
<td>In adulthood/ in childhood</td>
<td>Absence seizure</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>Micrognathia, long fingers, big low set ears, small mouth, height 172 cm</td>
<td>Learning difficulties</td>
</tr>
<tr>
<td>II-6</td>
<td>F, 46</td>
<td></td>
<td>In childhood/ in childhood</td>
<td>Absence seizures</td>
<td>No treatment</td>
<td>No treatment</td>
<td>Absent, height 176 cm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>II-7</td>
<td>M, -</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III-2</td>
<td>F, 25</td>
<td>Absent</td>
<td>Absent</td>
<td>ND</td>
<td>No treatment</td>
<td>Absent, height 155 cm</td>
<td>Absent, no treatment</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>III-3</td>
<td>F, 19</td>
<td>Absent</td>
<td>Absent</td>
<td>ND</td>
<td>No treatment</td>
<td>Small mouth, micrognathia, height 160 cm</td>
<td>Learning difficulties</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>III-4</td>
<td>M, -</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>No treatment</td>
<td>No treatment</td>
<td>Moderate intellectual disability</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>III-5</td>
<td>M, -</td>
<td>Absent</td>
<td>Absent</td>
<td>ND</td>
<td>No treatment</td>
<td>Absent</td>
<td>Absent</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>III-6</td>
<td>M, 25</td>
<td>Absent</td>
<td>Absent</td>
<td>ND</td>
<td>No treatment</td>
<td>No treatment</td>
<td>Unaffected</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
Table 1 Continued

<table>
<thead>
<tr>
<th>Individual</th>
<th>Sex, age at last follow-up</th>
<th>Seizures (onset/end in y)</th>
<th>Type of seizures</th>
<th>EEG</th>
<th>Treatment</th>
<th>Additional symptoms (morphological features)</th>
<th>Behavioural symptoms and development</th>
<th>GABRA3 variant</th>
<th>X-chromosome inactivation</th>
</tr>
</thead>
<tbody>
<tr>
<td>III-7</td>
<td>M, 21</td>
<td>Absent</td>
<td>Absent</td>
<td>ND</td>
<td>No treatment</td>
<td>Elongated skull, long neck, narrow and narrowly spaced palpebral fissures, sharply ended and long nose, arched palate, large protruding ears, sloping shoulders, long fingers, second and third toes – small syndactyly</td>
<td>Mild intellectual disability, learning difficulties, hyperactivity, disturbances of visual-motor integration, speech defect</td>
<td>c.497C &gt; T</td>
<td>p.T166M</td>
</tr>
<tr>
<td>III-9</td>
<td>F, 25</td>
<td>Absent</td>
<td>Absent</td>
<td>ND</td>
<td>No treatment</td>
<td>Absent</td>
<td>Absent</td>
<td>No</td>
<td>Delayed speech; mild intellectual disability</td>
</tr>
<tr>
<td>III-10</td>
<td>M, 23</td>
<td>17/17</td>
<td>Absence seizure</td>
<td>Generalized spike waves</td>
<td>No treatment</td>
<td>Horizontal nystagmus, micrognathia, elongated skull, arched palate, small mouth, long fingers, big low set ears, high stature (190 cm)</td>
<td>No</td>
<td>c.497C &gt; T</td>
<td>p.T166M</td>
</tr>
<tr>
<td>III-11</td>
<td>F -</td>
<td>Absent</td>
<td>Absent</td>
<td>ND</td>
<td>No treatment</td>
<td>Absent</td>
<td>Absent</td>
<td>No</td>
<td>Learning difficulties</td>
</tr>
<tr>
<td>III-12</td>
<td>F, 19</td>
<td>Absent</td>
<td>Absent</td>
<td>ND</td>
<td>No treatment</td>
<td>Small mouth, micrognathia, height 169 cm</td>
<td>No</td>
<td>c.497C &gt; T</td>
<td>p.T166M</td>
</tr>
<tr>
<td>III-13</td>
<td>M, 21</td>
<td>12/12</td>
<td>Absence seizures</td>
<td>Generalized spike waves</td>
<td>Valporate</td>
<td>Horizontal nystagmus, micrognathia, elongated skull, arched palate, small mouth, long fingers, big low set ears, high stature (182 cm)</td>
<td>Mild intellectual disability; delayed speech, starting at age 3 y</td>
<td>0.48 versus 0.52</td>
<td></td>
</tr>
</tbody>
</table>

Family F3 (Italy)

I-2 F | No | Normal | Intragenic GABRA3 duplication | 0.50 versus 0.50 |

II-1 F | Febrile seizure | Generalized tonic-clonic seizures | Generalized spike and polyspike and wave complexes | VPA, LEV, CLZ, CLB, ETX, PHB, FB | No | Borderline intellectual functioning | Intragenic GABRA3 duplication |

II-2 M | 3 | Partial complex, tonic-clonic | Frontal/central/ parasagittal focus | VPA, LEV, CBZ, CLB, diphantoin, LZP, OCB, FLX | No | Speech defect, IQ 72, anxiety, generalized fear, afraid to walk | c.1421A > G | p.Y474C |

Family F5

II-1 F | 12 | Complex partial complex, with tonic component | Central focus | Multidrug, neurovalgus stimulator, ketogenic diet | Microtia and strabismus surgery | Delayed language development, IQ earlier 65-70, now 50; autism like behaviour | c.1421A > G | p.Y474C |

Family F6 (France)

II-1 M | Speech starting at age 6; autism spectrum disorder | c.139G > A | p.G47R |

(continued)
occurring de novo, which could explain the observed severe phenotype. However, no other genetic defect likely to contribute to the disease phenotype could be detected (Supplementary Table 4).

While the genetic analysis of these three families provided evidence for the co-segregation with the complex disease phenotype, we further explored the role of de novo occurring GABRA3 variants. Diagnostic trio-based whole exome sequencing revealed a recurrent de novo variant, p.Y474C, c.1421A>G, in two sporadic females (Families 4 and 5) (Fig. 4A) presenting with partial seizures and mild-to-moderate intellectual disability. This variant affects transmembrane segment 4 of the receptor subunit and the replaced residue is highly conserved (Fig. 4B). The variant is not present in any of the control databases.

One more GABRA3 variant (c.139G>A, p.G47R) was identified in the X-chromosome exome-sequencing study (Family 6) (Table 1 and Fig. 5A). The male proband presented with autism spectrum disorder and severe learning disabilities, but no epileptic seizures. His brother, who does not carry the variant, is affected with a very similar phenotype (Table 1 and Fig. 5A). This variant is found at a somewhat less conserved part of the N-terminus of the a3-subunit (Fig. 5B). It has been identified in one male individual (allele frequency of 1.177/10 in ExAC) and in two individuals in gnomAD (allele frequency 1.163/25) (Supplementary Table 1). Furthermore, a different gene, SLC7A3, has been proposed to cause the phenotype in both brothers of this family (Nava et al., 2015).

We further searched for pathogenic variants in GABRA3 in a cohort of 238 independent families with classical GGE syndromes that underwent whole exome sequencing. In a female proband (Family F7, Fig. 5C), suffering from GGE with generalized tonic-clonic seizures (EGTCS), we identified one further missense variant (c.1007C>T, p.T336M) affecting a conserved threonine in the extracellular loop between transmembrane segments 2 and 3 (Fig. 5D). Her unaffected mother also carried the variant, in contrast to her affected sister (suffering from classical childhood absence epilepsy) and her affected father (experiencing few generalized tonic-clonic seizures). Moreover, in this family there were no signs of additional dysmorphic features as observed in the first two families (Supplementary material and Table 1).

Finally, to test for a significant enrichment of GABRA3 variants in our cohorts compared to controls, we compared the allele frequency of the non-synonymous GABRA3 variants in our patient cohorts of the known size—excluding the diagnostic services—(4/733) with missense, nonsense and splice site variants reported in the ExAC Browser (84/87765). This calculation showed a significant enrichment of GABRA3 variants in the patient cohort using Fisher’s exact test ($P < 0.01$).

Three out of the five missense variants are localized at the N-terminus of the a3-subunit (Fig. 6A), including the largely co-segregating variants from Families 1 (p.Q242L) and 2 (p.T166M) as well as the one found in the boy with
autism spectrum disorder (Family 6, p.G47R). The GGE-associated variant p.T336M affects the extracellular loop between transmembrane segments M2 and M3, whereas the de novo variant p.Y474C lies within the transmembrane segment M4 (Fig. 6A). We used *Xenopus laevis* oocytes and an automated two-microelectrode voltage clamp technique to assess the functional consequences of all identified variants. They were introduced in the cDNA encoding the human isoform of the GABAA receptor α3-subunit. After *in vitro* transcription, cRNAs encoding wild-type or mutant were co-injected with wild-type β2- and γ2s-subunits into oocytes and GABA-evoked ionic currents were recorded. We first investigated the effects of a high GABA concentration of 1 mM, closely mimicking physiological conditions when GABA is released into the synaptic cleft (Roth and Draguhn, 2012). This screening experiment revealed that all mutations, except p.G47R, led to a strong, statistically significant (**P < 0.0001 ANOVA on ranks, Dunn’s post hoc test) reduction of GABA-evoked currents compared to the wild-type (Fig. 6B and C). For p.Q242L, the currents were reduced by 85 ± 3%, for p.T166M by 75 ± 3%, for p.Y474C by 68 ± 9%, for p.G47R by 46 ± 10% and for p.T336M by 91 ± 2% (Fig. 6B and C). Further investigation showed diminished responses to different GABA concentrations in the whole concentration range (Fig. 6D). Interestingly, the GABA sensitivity was increased for p.Q242L, p.Y474C and p.T336M variants compared to the wild-type (EC50 of 25 ± 2; 22 ± 7; 38 ± 4 and 96 ± 3 μM for mutants and wild-type, respectively). However, this shift was not predicted to compensate for the pronounced decline of current amplitudes (Fig. 6D). Western blot analysis of oocytes injected with wild-type or mutant α3β2γ2s receptors performed using an anti-α3-subunit antibody revealed a statistically significant decrease in the total amount of protein only for p.T166M compared to the wild-type (Fig. 6E and F) (**P < 0.05, ANOVA on ranks, Dunn’s post hoc test).

**Discussion**

Our results suggest that GABRA3 is a new gene associated with epilepsy and related disorders. In total, this study identified five missense variants and a microduplication within this gene. We provide strong genetic evidence for the pathogenicity of the fully co-segregating variant detected in Family 1. Family 2 is more complex, and the variant detected in this family, which largely co-segregated with epilepsy-related phenotypes in male and female carriers, is also found in an unaffected male, and one male affected only with intellectual disability. Especially Family 1 supports the pattern of X-linked inheritance, with males
being more severely affected than females. This inheritance pattern also fits Family 3, since the boy in this family carrying a duplication with deleterious effects on \textit{GABRA3} expression also presented with severe epileptic encephalopathies in contrast to his unaffected mother. The detection of a recurrent \textit{de novo} variant associated with a severe epileptic encephalopathies phenotype in females corroborates a role of this gene in epilepsy and related disorders. Moreover, \textit{in vitro} analysis revealed that the severely affected individuals carried variants with a large functional deficit corresponding to at least a 70\% reduction of GABA-evoked currents.

We also report two families in which \textit{GABRA3} cannot be regarded as an obvious disease gene, but might act as a risk factor contributing to the development of disease in some mutation carriers. This is seen both in the patient with autism spectrum disorder (Family 6) and in the female with mild epilepsy (Family 7 with GGE). In both families, clearly affected individuals do not carry \textit{GABRA3} variants, suggesting a dominant role of a different gene. In Family 6, this gene has already been suggested (Nava \textit{et al.}, 2015). Moreover, the \textit{GABRA3} variant detected in Family 6 showed a milder functional defect. The p.T336M amino acid exchange, which did show a very severe loss of function, was only found in two females within the GGE family, the unaffected mother and one of the affected sisters, but not in the other affected sister and the affected father. The incomplete co-segregation, as well as the fact that female mutation carriers from other families do not present with classical GGE syndromes, suggest that further factors or variants are involved in the pathogenesis within this family. However, these could not be identified by exome sequencing of the whole family (Supplementary Table 3).

The detected variants are associated with a large spectrum of neuropsychiatric symptoms, ranging from severe epileptic encephalopathies with dysmorphic features and nystagmus to relatively mild intellectual disability without epilepsy and one unaffected individual among the male mutation carriers. In females, the phenotypic spectrum extends...
from normal, i.e. without detectable clinical signs for epilepsy, intellectual disability or dysmorphisms, to mildly affected with well treatable seizures, moderate developmental delay and similar dysmorphic features and nystagmus as in males. This spectrum is further extended to the severe end in one of the de novo mutation carriers presenting with pharmacoresistant seizures in addition to moderate intellectual disability. We hypothesized that variable X-inactivation may contribute to the large phenotypic variability in females, but an X-inactivation test performed in leucocyte DNA from eight mutation carriers (affected \( n = 4 \), unaffected \( n = 4 \)) did not identify any correlation with the affection status (Table 1). However, the X-inactivation pattern in the nervous system can differ from that seen in blood, as reported for Rett syndrome (Gibson et al., 2005), so that we cannot exclude that X-inactivation plays a role in the phenotypic variability observed in female mutation carriers.

A broad phenotypic spectrum is well known from other epilepsy genes including those coding for different GABA\(_A\) receptor subunits (Harkin et al., 2007; Carvill et al., 2014; Epi4K Consortium, 2016; Johannesen et al., 2016; Papandreou et al., 2016; Möller et al., 2017). Our results suggest that a combination of the severity of the mutation-induced GABA\(_A\) receptor dysfunction and the ‘genetic background’, i.e. so far unknown modifying genetic factors that could not be identified in our exome sequencing studies, are responsible for the observed clinical phenotypic variability. The latter may play a role for example in the two different branches of Family 2 presenting males with large differences in clinical severity.

Some GABRA genes have further been linked to severe forms of epilepsy, such as Dravet syndrome (GABRA1) (Carvill et al., 2014; Johannesen et al., 2016), or Lennox–Gastaut syndrome (GABRB3) (Epi4K Consortium et al., 2013). Genetic studies have shown that many of the most severe epileptic encephalopathies are caused by de novo mutations (Claes et al., 2001; Harkin et al., 2002; Kalscheuer et al., 2003; Tao et al., 2004; Veeramah et al., 2012; Weckhuysen et al., 2012; Epi4K Consortium et al., 2013; Suls et al., 2013; Carvill et al., 2014; Nava et al., 2014; Blanchard et al., 2015; Syrbe et al., 2015; Epi4K Consortium, 2016; Johannesen et al., 2016; Shen et al., 2017), which is confirmed by our findings in one of the de novo mutation carriers. However, our results also indicate that mildly affected female carriers can transfer severe mutations to their children, which can result in devastating epileptic encephalopathies and intellectual disability in

![Figure 5](https://example.com/figure5.png)

**Figure 5** GABRA3 variants identified in Family 6 with autism-like disorder and in Family 7 with GGE. (A) Family 6 pedigree showing the presence of the p.G47R G\(_A\) variant in the index case who presented with speech delay, autism spectrum disorder or behavioural disturbances and his mother. (B) Alignment depicting the evolutionary conservation of the p.G47 amino acid. (C) Family 7 pedigree showing the co-segregation of the p.T336M variant with the phenotype in this GGE family. (D) Alignment depicting the evolutionary conservation of the p.T336 amino acid. ID = intellectual disability; WES = whole exome sequencing.
the sons and therefore constitutes an important aspect of genetic counseling in these families with X-linked-like inheritance.

Reduced amplitudes of GABA-evoked currents were observed for all five detected variants. This loss-of-function effect has been a common feature of all GABA\(_A\) receptor mutations associated with epilepsy and proposed to impair the GABA\(_A\) receptor-mediated inhibition leading to an increased neuronal hyperexcitability and seizures (Baulac et al., 2001; Wallace et al., 2001; Harkin et al., 2002; Maljevic et al., 2006; Johannesen et al., 2016; Møller et al., 2017). The suggested molecular mechanisms include gating defects, reduced GABA sensitivity, or reduced surface expression due to protein misfolding, impaired assembly or trafficking defects (Wallace et al., 2001; Harkin et al., 2002; Maljevic et al., 2006; Macdonald et al., 2012; Johannesen et al., 2016; Kang and Macdonald, 2016; Møller et al., 2017). Messenger RNA and protein degradation of defective GABA\(_A\) receptor subunits have also been shown (Gallagher et al., 2005; Maljevic et al., 2006; Kang and Macdonald, 2016). In our study, only one (p.T166M) of the five GABRA3 variants showed a significantly lower amount of protein in total lysates obtained from injected Xenopus oocytes, indicating that at least for

Figure 6 Functional analysis of the identified GABRA3 variants in Xenopus laevis oocytes. (A) Schematic representation of the \(\alpha_3\)-subunit of the GABA\(_A\) receptor including the predicted positions of all mutated amino acids. (B) Representative examples of current responses to application of 1 mM GABA recorded from Xenopus oocytes expressing \(\alpha_3\beta_2\gamma_2\) receptors comprising wild-type or mutant (p.Q242L, p.T166M, p.Y474C, p.G47R, p.T336M) \(\alpha_3\)-subunits. (C) Normalized current response to 1 mM GABA application for wild-type (n = 137), p.Q242L (n = 29), p.T166M (n = 37), p.Y474C (n = 22), p.G47R (n = 10) and p.T336M (n = 28) mutations; \(***P < 0.0001\) ANOVA on ranks, Dunn's post hoc test. The reduction in current amplitude was 85 ± 3% for p.Q242L; 75 ± 3% p.T166M; 68 ± 9% for p.Y474C; 46 ± 10% for p.G47R and 91 ± 2% for p.T336M in comparison with the wild-type. (D) Dose-response curve for \(\alpha_3\beta_2\gamma_2\) wild-type (n = 77), p.Q242L (n = 16), p.T166M (n = 25), p.Y474C (n = 9), p.G47R (n = 19) and p.T336M (n = 14) receptors recorded upon application of different GABA concentrations (in \(\mu M\): 1, 3, 10, 40, 100, 300 and 1000) and normalized to the maximal response (1000 \(\mu M\)) for each cell. Statistically significant differences between the EC\(_{50}\) values were verified by ANOVA on ranks and Dunn's post hoc test \((***P < 0.0001)\) for p.Q242L, p.Y474C and p.T336M). The predicted dose-response curves, calculated from the current amplitude ratio of the mutant versus wild-type response to the application of 1 mM GABA (see C) are shown as dashed lines for all mutations. (E) Western blot analysis of whole cell lysates from Xenopus oocytes injected with cRNA encoding for \(\alpha_3\beta_2\gamma_2\) wild-type or mutated subunits. All lysates show a band of the expected size for the \(\alpha_3\)-subunit protein (55 kDa). (F) Quantification of western blots revealing a significant reduction of the \(\alpha_3\)-subunit signal for the T166M mutant \((n = 4)\). *\(P < 0.05\) using ANOVA on ranks with Dunn's post hoc test.
this variant a less stable protein is the cause for the observed reduced current amplitudes.

Interestingly, three of the analysed five variants showed an increased GABA sensitivity. Since the amplitudes of GABA-evoked anion currents carried by the respective mutant receptors were strongly diminished, we estimated the combined effect of the amplitude reduction and the shift in GABA-sensitivity, which revealed that the effect of this shift may only have a minor gain-of-function effect at low GABA concentrations. At higher GABA concentrations, such as 1 mM, which is considered to represent the GABA concentration in the synaptic cleft (Roth and Draguhn, 2012), a severe loss-of-function remained obvious. However, this repeatedly identified functional alteration may suggest that other complex mechanisms, possibly including pre- or extrasynaptic processes may underlie pathology associated with the z3-subunit variants. The role of the z3-subunit in tonic inhibition has been demonstrated in principal cells of the amygdala (Marowsky et al., 2012). Furthermore, the fact that GABA_A receptors containing z3-subunits show a higher affinity for GABA compared to those containing z2-subunits (Keramidas and Harrison, 2010) might also indicate their extrasynaptic role.

In the rodent brain, the z3-subunit of the GABA_A receptor has a broad distribution and is specifically expressed in the thalamus, being the only z-subunit expressed in the nucleus reticularis thalami (nRT) (Pirker et al., 2000; Hört nagl et al., 2013). Knockout mice lacking this subunit do not show spontaneous seizures. On the contrary, they show an enhanced intra nucleus reticularis thalami inhibition and a reduced susceptibility to pharmacologically induced seizures, probably due to a strong compensatory mechanism increasing the expression of a different z-subunit variants. (Schofield et al., 2009). However, in a mouse model in which the benzodiazepine binding site of the z3-subunit is disrupted, an increase in spike and wave discharges, a characteristic of absence seizures, was found (Christian et al., 2013). This suggests that an impaired function of the z3-subunit may lead to epileptic seizures, which are not detected in knockout animals because of an adaptive process or compensatory mechanism.

Dysmorphic features are observed in the two families with the most severe phenotypes in most affected mutation carriers and partially overlap between the two families. Also one of the de novo mutation carriers showed a (different) dysmorphism. How a subunit of GABA_A receptors may be linked to changes in morphology is not clear, although it has been reported that homozygous Gabrb3 knockout mice exhibit a cleft palate in about half of the cases and the other half have feeding difficulties as neonates (DeLorey et al., 1998). The observed nystagmus may be attributed to a particular inhibitory function of GABA_A receptor z3-subunits in the brainstem or cerebellum. Expression of GABRA3 in these structures has been shown using specific antibodies against this subunit (Pirker et al., 2000).

In summary, we have detected GABRA3 variants in patients with a spectrum of neuropsychiatric disorders and demonstrated in our in vitro assay that they cause loss-of-function effects. The data obtained from whole exome sequencing in the affected families suggest that GABRA3 variants present the major underlying genetic component of the observed disease phenotype in three and a contributing factor in two families. Detection of a recurrent de novo variant associated with a severe clinical picture corroborates these findings suggesting GABRA3 as a new epilepsy gene.

**Acknowledgements**

We dedicate this work to our colleague Esther Leshinsky-Silver who initiated the study by identifying the first GABRA3 mutation and sadly passed away during the reviewing process of this manuscript.

We thank all the families who participated in this research and Prof. S. Schweiger for her critical reading, Prof. S. Petrou for providing the GABRA3 clone, Heidi Loeffer and Nicole Zepezauer for excellent technical assistance. Some of the computational results presented in this paper were carried out using the HPC facilities of the University of Luxembourg (http://hpc.uni.lu).

**Funding**

Parts of this work were financed by the EU FP7 project GENCODYS, grant number 241995, by the Polish Ministry of Science and Higher Education, grant number 2014/15/D/NZ5/03426, by the Italian Ministry of Health (project RF-2010-2314356 to F.Z. and GR-2009-1473821 to P.S.), by the European Science Foundation Eurocores project EuroEPINOMICS (CoGIE) (DFG Le1030/11-1 to H.L. and S.M.), and by the Federal Ministry for Education and Research (BMBF, program on rare diseases, IonNeurONet: 01GM1105A, to S.M., H.L., S.B.).

**Supplementary material**

Supplementary material is available at Brain online.

**References**


Kang JQ, Macdonald RL. Molecular pathogenic basis for GABRG2 mutations associated with a spectrum of epilepsy syndromes, from generalized absence epilepsy to Dravet syndrome. JAMA Neurol 2016; 73: 1009–16.

Keramidas A, Harrison NL. The activation mechanism of alpha1beta2gamma2S and alpha3beta3gamma2S GABAA receptors. J Gen Physiol 2010; 135: 59–75.


